TAT Congress series

Get a glimpse of future cancer therapies at the annual TAT congress!

TAT provides a forum for in-depth discussion of emerging targeted agents for the treatment of cancer. The TAT series was established in 2002 and is offered by the NDDO Education Foundation, in a partnership with the European Society for Medical Oncology (ESMO). TAT 2012 is co-sponsored by the National Cancer Institute (NCI) of the USA.

TAT meetings are characterized by:

• Focus on innovative agents with a cancer-specific molecular target, in particular the most promising ones in early-phase clinical development;
• Updates on approved targeted agents undergoing further clinical development for cancer therapy;
• Top-level international program committee and faculty, warranting high scientific standards;
• Educational value for medical specialists and drug development professionals in oncology;
• A completely plenary program allowing delegates to focus and not miss anything;
• Opportunities to present early-phase clinical trials and translational research in front of an expert audience;
• Medium-sized in terms of the number of delegates;
• Attention to methodological and regulatory issues in anticancer drug development.

TAT meetings usually attract a mix of professionals with different backgrounds and functions in academia, industry and governmental agencies, all having a profound interest in the development of innovative cancer therapies.

As of 2011, TAT congresses are held annually in Europe, with the venue alternating between Paris (odd years) and Amsterdam (even years). TAT meetings are usually held in the first half of March.